Automated Quantification of Radiologic Pulmonary Alteration During Acute Respiratory Failure: Application to the COVID-19 Pandemic (QUANTICO-PRO)

June 5, 2026 updated by: University Hospital, Strasbourg, France

Automated Quantification of Radiologic Pulmonary Alteration During Acute Respiratory Failure: Application to the COVID-19 Pandemic : Prospective Multicenter Cohort Study

Automated quantification of the pulmonary volume impaired during acute respiratory failure could be helpful to assess patient severity during COVID-19 infection or perioperative medicine, for example.

This study aims at assessing the correlation between the amount of radiologic pulmonary alteration and the clinical severity in two clinical situation :

  1. SARS-CoV-2 infections
  2. Postoperative hypoxemic acute respiratory failure.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

500

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Nancy, France, 54500
        • Service d'anesthésie réanimation-CHU de Nancy
      • Strasbourg, France, 67098
        • Service d'Anesthésie-Réanimation - CHU Strasbourg

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Subject admitted to a care unit of the University Hospitals of Strasbourg or the University Hospital of Nancy and presenting a suspicion of SARS-CoV-2 infection or postoperative hypoxemic respiratory failure
  • Able to understand the objectives and risks of the research and to give dated and signed informed consent.

Subjects may also be included in emergency or immediate life-threatening situations.

  • Subject with insurance covering

Exclusion Criteria:

  • Pregnant woman (pregnancy confirmed by a urine or blood test)
  • Subject usually on home oxygen therapy
  • Subject under court protection
  • Subject under guardianship or curatorship

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Thoracic CT Scan
Radiation: Thoracic CT scan
Automated quantitative analysis of altered pulmonary volume

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Correlation between altered pulmonary volume and ordinal severity scale
Time Frame: 2 days after CT scan (Day 2)
This criterion will be expressed as a score between 1 (least severe) and 7 (most severe).
2 days after CT scan (Day 2)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Correlation between altered pulmonary volume and ordinal severity scale
Time Frame: 7 days after CT scan (Day 7)
This criterion will be expressed as a score between 1 (least severe) and 7 (most severe).
7 days after CT scan (Day 7)
Mortality
Time Frame: 90 days following CT scan (Day 90)
90 days following CT scan (Day 90)
Rate of admission to intensive care unit
Time Frame: 28 days following CT scan (Day 28)
28 days following CT scan (Day 28)
Initial length of hospitalization stay (in days)
Time Frame: 90 days following CT scan (Day 90)
90 days following CT scan (Day 90)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Strasbourg, France

Collaborators

REGION GRAND EST
E-MEDIA
VISIBLE PATIENT

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 13, 2022

Primary Completion (Actual)

April 8, 2025

Study Completion (Estimated)

June 1, 2027

Study Registration Dates

First Submitted

March 11, 2022

First Submitted That Met QC Criteria

March 11, 2022

First Posted (Actual)

March 14, 2022

Study Record Updates

Last Update Posted (Actual)

June 8, 2026

Last Update Submitted That Met QC Criteria

June 5, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 8138

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe